The most aggressive, triple-negative breast cancer (TNBC), lacks expression of valid predictive markers [oestrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2)], and thus devoid of clear therapeutic targets, it presents a serious clinical challenge. This evidence concerns the gene PGR and triple-negative breast carcinoma.